• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硝苯地平的药代动力学与代谢

Pharmacokinetics and metabolism of nifedipine.

作者信息

Raemsch K D, Sommer J

出版信息

Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18.

DOI:10.1161/01.hyp.5.4_pt_2.ii18
PMID:6862586
Abstract

Nifedipine is almost completely absorbed from the gastrointestinal tract as shown by plasma levels after sublingual, oral, and rectal administration. Because of presystemic metabolism, the bioavailability is about 56% to 77%. After oral administration of 10 mg, the mean plasma concentration of nifedipine reaches maximum values of 160 +/- 49 micrograms/liter after 30 to 60 minutes. After 8 hours, the mean concentration drops to 3.4 +/- 1.2 micrograms/liter. After intravenous administration (0.015 mg/kg) biphasic elimination occurs, the half-life of the alpha-phase being about 13 minutes and of the beta-phase 1.26 +/- 0.55 hours in healthy volunteers. After oral administration of higher doses (40 mg) and after continuous infusion over 24 hours, a third phase with a half-life of about 8 hours can be seen. The apparent volume of distribution of the central compartment (Vce) is 0.294 +/- 0.1 l/kg, and the total body clearance amounts to 0.45 +/- 0.1 liter/hr . kg. Nifedipine is eliminated from the body by hepatic metabolism to the major metabolites 2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid (M I) and the corresponding 2-hydroxymethyl-pyridinecarboxylic acid (M II). Methods for the quantitative detection of unchanged nifedipine in the presence of the pyridine analog in plasma (HPLC) and of the main metabolites in plasma and urine (GLC) have been developed. A simple semiquantitative method for detecting metabolites in urine (HPTLC) can be used to monitor patient compliance.

摘要

硝苯地平经舌下、口服和直肠给药后,血浆水平表明其几乎可从胃肠道完全吸收。由于存在首过代谢,其生物利用度约为56%至77%。口服10毫克后,硝苯地平的平均血浆浓度在30至60分钟后达到最大值160±49微克/升。8小时后,平均浓度降至3.4±1.2微克/升。静脉给药(0.015毫克/千克)后出现双相消除,在健康志愿者中,α相半衰期约为13分钟,β相半衰期为1.26±0.55小时。口服较高剂量(40毫克)后以及连续输注24小时后,可观察到半衰期约为8小时的第三相。中央室的表观分布容积(Vce)为0.294±0.1升/千克,全身清除率为0.45±0.1升/小时·千克。硝苯地平在体内通过肝脏代谢为主要代谢产物2,6-二甲基-4-(2-硝基苯基)-5-甲氧基羰基吡啶-3-羧酸(M I)和相应的2-羟甲基吡啶羧酸(M II)。已经开发出在血浆中吡啶类似物存在的情况下定量检测未改变的硝苯地平的方法(高效液相色谱法)以及检测血浆和尿液中主要代谢产物的方法(气相色谱法)。一种简单的半定量检测尿液中代谢产物的方法(薄层扫描法)可用于监测患者的依从性。

相似文献

1
Pharmacokinetics and metabolism of nifedipine.硝苯地平的药代动力学与代谢
Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18.
2
Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.硝苯地平胃肠治疗系统的临床药代动力学。一种硝苯地平控释制剂。
Am J Med. 1987 Dec 21;83(6B):10-4. doi: 10.1016/0002-9343(87)90630-9.
3
Pharmacokinetics of nicardipine following oral and intravenous administration in man.硝苯地平在人体口服和静脉给药后的药代动力学。
Postgrad Med J. 1984;60 Suppl 4:7-10.
4
Nifedipine: kinetics and dynamics in healthy subjects.硝苯地平:健康受试者的动力学与动态变化
Clin Pharmacol Ther. 1984 Jun;35(6):742-9. doi: 10.1038/clpt.1984.105.
5
Felodipine kinetics in healthy men.
Clin Pharmacol Ther. 1985 Aug;38(2):205-11. doi: 10.1038/clpt.1985.160.
6
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.硝苯地平:肾功能对药代动力学/血流动力学关系的影响。
Clin Pharmacol Ther. 1985 May;37(5):563-74. doi: 10.1038/clpt.1985.89.
7
Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects.硝苯地平片的药代动力学研究。与降压效果的相关性。
Hypertension. 1983 Jul-Aug;5(4 Pt 2):II29-33. doi: 10.1161/01.hyp.5.4_pt_2.ii29.
8
The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.氨氯地平在健康志愿者单次静脉注射和口服给药后,以及每日一次重复口服给药14次后的药代动力学。
Br J Clin Pharmacol. 1986 Jul;22(1):21-5. doi: 10.1111/j.1365-2125.1986.tb02874.x.
9
The first pass metabolism of nifedipine in man.硝苯地平在人体中的首过代谢。
Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
10
Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.硝苯地平在正常受试者单次静脉注射和口服后的动力学及生物利用度。
J Clin Pharmacol. 1983 Apr;23(4):161-70. doi: 10.1002/j.1552-4604.1983.tb02720.x.

引用本文的文献

1
Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor.
J Clin Endocrinol Metab. 2025 Sep 16;110(10):2752-2761. doi: 10.1210/clinem/dgaf081.
2
Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort.具有和不具有降低白细胞介素-6特性的抗高血压药物对长期血压控制的影响:前瞻性HELIUS队列研究
Int J Cardiol Cardiovasc Risk Prev. 2024 Dec 11;24:200358. doi: 10.1016/j.ijcrp.2024.200358. eCollection 2025 Mar.
3
Updates on Intrinsic Medicinal Chemistry of 1,4-dihydropyridines, Perspectives on Synthesis and Pharmacokinetics of Novel 1,4-dihydropyrimidines as Calcium Channel Blockers: Clinical Pharmacology.1,4 - 二氢吡啶的内在药物化学进展,新型1,4 - 二氢嘧啶作为钙通道阻滞剂的合成与药代动力学展望:临床药理学
Curr Top Med Chem. 2025 Jan 1. doi: 10.2174/0115680266323908241114064318.
4
Exploring the multiple effects of nifedipine and captopril administration in spontaneously hypertensive rats through pharmacokinetic-pharmacodynamic analyses.通过药代动力学-药效学分析探索硝苯地平和卡托普利对自发性高血压大鼠的多种作用。
Pharmacol Res Perspect. 2024 Aug;12(4):e1249. doi: 10.1002/prp2.1249.
5
Complex Spectroscopy Studies of Nifedipine Photodegradation.硝苯地平光降解的复杂光谱研究
Pharmaceutics. 2023 Nov 10;15(11):2613. doi: 10.3390/pharmaceutics15112613.
6
Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment.重复生脉散给药对硝苯地平药代动力学的影响及合用的风险/获益。
J Food Drug Anal. 2022 Mar 15;30(1):111-127. doi: 10.38212/2224-6614.3401.
7
The Hantzsch reaction for nitrogen-13 PET: preparation of [N]nifedipine and derivatives.氮-13 PET 的 Hantzsch 反应:[N]硝苯地平及其衍生物的制备。
Chem Commun (Camb). 2021 May 18;57(40):4962-4965. doi: 10.1039/d1cc00495f.
8
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.应用生理药代动力学(PBPK)模型预测药物-食物相互作用:行业视角。
AAPS J. 2020 Sep 27;22(6):123. doi: 10.1208/s12248-020-00508-2.
9
Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.鉴定钙通道阻滞剂在人诱导多能干细胞衍生心肌细胞中的转录组特征。
Circ Res. 2019 Jul 5;125(2):212-222. doi: 10.1161/CIRCRESAHA.118.314202. Epub 2019 May 13.
10
Immediate-Release Nifedipine Binary Dry Powder Mixtures with Nanocellulose Featuring Enhanced Solubility and Dissolution Rate.具有增强溶解度和溶解速率的含纳米纤维素的速释硝苯地平二元干粉混合物。
Pharmaceutics. 2019 Jan 18;11(1):37. doi: 10.3390/pharmaceutics11010037.